Eph receptor B6 shapes a cold immune microenvironment, inhibiting anti-cancer immunity and immunotherapy response in bladder cancer

Xiaolong Jia; Dongxu Zhang; Cheng Zhou; Zejun Yan; Zhaohui Jiang; Liping Xie; Junhui Jiang

doi:10.3389/fonc.2023.1175183

Eph receptor B6 shapes a cold immune microenvironment, inhibiting anti-cancer immunity and immunotherapy response in bladder cancer

Front Oncol. 2023 Aug 9:13:1175183. doi: 10.3389/fonc.2023.1175183. eCollection 2023.

Authors

Xiaolong Jia^{1

2}, Dongxu Zhang^{1

2}, Cheng Zhou^{1

2}, Zejun Yan², Zhaohui Jiang², Liping Xie¹, Junhui Jiang²

Affiliations

¹ Department of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
² Department of Urology, Ningbo First Hospital, Ningbo Hospital of Zhejiang University, Ningbo, China.

Abstract

Background: The role of Eph receptors and related ephrin (EFN) ligands (as the largest family of transmembrane-bound RTKs) in immunomodulation in many types of cancer, especially bladder cancer (BLCA), is scarcely known.

Methods: A pan-cancer dataset was retrieved from The Cancer Genome Atlas (TCGA) to explore the relation between Eph receptor/EFN ligand family genes and immunomodulators and tumor-infiltrated immune cells (TIICs). Local BLCA, GSE32894, and GSE31684 cohorts were applied to validate. The IMvigor210 cohort was employed to explore the relationship between EPHB6 and immunotherapy response. Moreover, association between EPHB6 and molecular subtype was investigated to explore potential therapeutic strategies. Immunohistochemical staining of CD8 and CD68 was performed to validate the correlation between EPHB6 and TIICs.

Results: The pan-cancer analysis revealed variations in the immunological effects of Eph receptor/EFN ligand family genes across different types of cancer. EPHB6 expression negatively correlated with the expression of the majority of immunomodulators (including HLA and immune checkpoints), and CD8 T cells and macrophages in both the TCGA-BLCA and validation BLCA cohorts, shaping a cold immune microenvironment with inhibited immunity. In the IMvigor210 cohort, patients with high-EPHB6 highly correlated with a non-inflamed, low PD-L1 expression immune phenotype, and correspondingly, with less responders to immunotherapy. The high-EPHB6 group, enriched with the basal subtype, presented significantly fewer TP53 and more FGFR3 genomic alterations. Finally, a novel EPHB6-related Genes signature, with reliable and robust ability in prognosis prediction, was constructed.

Conclusions: This study comprehensively investigated the immunological effects of Eph receptor/EFN ligand family genes pan-cancer, and specially identified the immunosuppressive role of EPHB6 in BLCA. Furthermore, EPHB6 may predict the molecular subtype and prognosis of BLCA, and serve as a novel therapeutic target to improve the sensitivity of immunotherapy.

Keywords: EPHB6; bladder cancer; immunomodulator; immunotherapy; molecular subtype; prognostic signature; tumor microenvironment.

Grants and funding

This work was supported by the following funding: (1) Medical and Health Science and Technology Plan Project of Zhejiang Province, No.2019KY575, No.2020ZH007, No.2021KY995); (2) Zhejiang Natural Science Fund (LTGY23H050002); (3) Ningbo Top Medical and Health Research Program (No.2022020203)